E

Is more better or is less more?

It’s time to take five lung cancer trials, put them through their paces and explain why all may not…

April 3, 2025
E

The End and the Beginning

A deeper look at the latest PD-L1 x VEGF bispecific data

March 31, 2025
E

Addressing acquired resistance through novel combination strategies

All aboard to hear more about novel targeted therapy combination strategies...

April 8, 2022
E

What are neoantigens and why do they matter in cancer immunotherapy?

A primer on neoantigens and their importance in cancer research

August 9, 2016
E

Osimertinib front-line data wows European Lung 2016

First-line data for AstraZeneca’s ($AZN) third generation EGFR inhibitor osimertinib (Tagrisso) impresses at the 2016 European Lung Cancer Conference in Geneva.

April 14, 2016